Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Pflugers Arch ; 474(7): 743-752, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35585327

RESUMEN

Since damage induced by ischemia-reperfusion (I/R) involves alterations in Ca2+ homeostasis and is reduced by ischemic postconditioning (IP) and that CoCl2 can trigger changes resembling the response to a hypoxic event in normoxia and its blockade on Ca2+ current in heart muscle, our aim was to evaluate CoCl2 as an IP therapeutic tool. Mechanic and energetic parameters of isolated and arterially perfused male Wistar rat heart ventricles were simultaneously analyzed in a model of I/R in which 0.23 mmol/L CoCl2 was introduced upon reperfusion and kept or withdrawn after 20 min or introduced after 20 min of reperfusion. The presence of CoCl2 did not affect diastolic pressure but increased post-ischemic contractile recovery, which peaked at 20 min and decreased at the end of reperfusion. This decrease was prevented when CoCl2 was removed at 20 min of reperfusion. Total heat release increased throughout reperfusion, while economy increased between 15 and 25 min. No effect was observed when CoCl2 was introduced at 20 min of reperfusion. In addition, both the area under the contracture curve evoked by 10 mmol/L caffeine-36 mmol/L Na+ and the contracture tension relaxation rate were higher with CoCl2.Furthermore, CoCl2 decreased the number of arrhythmias during reperfusion and the ventricular damaged area. The presence of CoCl2 in reperfusion induces cardioprotection consistent with the improvement in cellular calcium handling. The use of CoCl2 constitutes a potential cardioprotective tool of clinical relevance.


Asunto(s)
Contractura , Enfermedad de la Arteria Coronaria , Poscondicionamiento Isquémico , Daño por Reperfusión Miocárdica , Animales , Cobalto , Isquemia , Masculino , Reperfusión Miocárdica , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Ratas , Ratas Wistar
2.
Can J Neurol Sci ; 47(3): 336-343, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31928559

RESUMEN

BACKGROUND: Pain is a non-motor symptom in Parkinson's disease (PD) which commonly goes underreported. Adequate treatment for pain in PD remains challenging, and to date, no clear guidelines for management are available. METHODS: With the goal of understanding and organizing the current status of pain management in PD, we conducted a review of pharmacological and non-pharmacological treatments for pain in patients with PD. Suitable studies cataloged in PubMed and the Cochrane database up to October 31, 2019, were included prioritizing randomized controlled trials. Post-hoc analyses and open-label studies were also included. RESULTS: Treatment with levodopa increases pain thresholds in patients with PD. Apomorphine did not have similar efficacy. Duloxetine provided benefit in an open-label trial. Oxycodone-naloxone PR did not have a significant improvement in pain, but per-protocol analysis showed a reduction in pain when adherence was strong. Rotigotine patch had numerical improvement on pain scales with no statistical significance. Safinamide significantly improved the "bodily discomfort" domain in the PDQ-39 questionnaire. Botulinum toxin A had a non-significant signal toward improving dystonic limb pain in PD. DBS to the subthalamic nucleus may modulate central pain thresholds, and a pilot study of cranioelectric therapy warrants future research in the area. CONCLUSION: After optimizing dopaminergic therapy, understanding the type of pain a patient is experiencing is essential to optimizing pain control in PD. While recommendations can be made regarding the treatment options in each domain, evidence remains weak and future randomized controlled studies are needed.


Asunto(s)
Inhibidores de la Liberación de Acetilcolina/uso terapéutico , Analgésicos/uso terapéutico , Antiparkinsonianos/uso terapéutico , Estimulación Encefálica Profunda , Agonistas de Dopamina/uso terapéutico , Dolor/tratamiento farmacológico , Enfermedad de Parkinson/terapia , Alanina/análogos & derivados , Alanina/uso terapéutico , Apomorfina/uso terapéutico , Bencilaminas/uso terapéutico , Toxinas Botulínicas Tipo A/uso terapéutico , Combinación de Medicamentos , Clorhidrato de Duloxetina/uso terapéutico , Humanos , Levodopa/uso terapéutico , Naloxona/uso terapéutico , Oxicodona/uso terapéutico , Dolor/fisiopatología , Manejo del Dolor , Dimensión del Dolor , Umbral del Dolor , Enfermedad de Parkinson/fisiopatología , Tetrahidronaftalenos/uso terapéutico , Tiofenos/uso terapéutico
4.
Mov Disord Clin Pract ; 7(2): 140-153, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32071931

RESUMEN

BACKGROUND: Psychotic symptoms, such as delusions and hallucinations, are part of the clinical picture of several conditions presenting movement disorders. Phenomenology and epidemiology of psychosis in Parkinson's disease have received wide attention; however, the presence of psychosis in other movement disorders is, comparatively, less well known. OBJECTIVES: To review psychotic symptoms present in different movement disorders. METHODS: A comprehensive and structured literature search was performed to identify and analyze data on patients with movement disorders and comorbid psychosis. RESULTS: In monogenic parkinsonisms, such as PARK-GBA, PARK-LRRK2, and PARK-SNCA, visual hallucinations related to dopamine replacement therapy are frequent as well as are delusions in PARK-LRRK2 and PARK-SNCA, but not in PARK-GBA. Different types of delusions and hallucinations are found in Huntington's disease and other choreic disorders. In Tourette's syndrome, paranoid delusions as well as visual, olfactory, and auditory hallucinations have been described, which usually develop after an average of 10 years of disease. Delusions in ataxias are more frequent in ATX-TBP, ATX-ATN1, and ATX-ATXN3, whereas it is rare in Friedreich's ataxia. Psychosis is also a prominent and frequent clinical feature in Fahr's disease, Wilson's disease, neurodegeneration with brain iron accumulation, and some lysosomal storage disorders, whereas it is uncommon in atypical parkinsonisms and dystonia. Psychosis usually occurs at late disease stages, but may appear as onset symptoms of the disease, especially in Wilson's disease, Huntington's disease, late-onset Tays-Sachs, and Niemann-Pick. CONCLUSION: Psychosis is a frequent comorbidity in most hyper- and hypokinetic movement disorders. Appropriate recognition is relevant both in the early and late disease stages.

5.
Artículo en Español | LILACS, BINACIS | ID: biblio-1353929

RESUMEN

Introducción: Se entiende por lesión catastrófica a cualquier trauma grave que comprometa la cabeza, el cerebro, la columna vertebral o la médula espinal, que pone en riesgo la vida o puede dejar una discapacidad permanente o semipermanente. En la Argentina, la incidencia de lesionados en el ámbito del rugby es alta comparada con la de otros países. En los últimos años, se han implementado múltiples medidas de prevención y se han modificado normas con el objetivo de evitar las lesiones catastróficas. materiales y métodos: Se analizaron datos obtenidos de una encuesta telefónica realizada en el marco de colaboración entre la Unión Argentina de Rugby y la Fundación para la Lucha de Enfermedades Neurológicas de la Infancia (Fleni). Se realizó un análisis descriptivo de los datos. Se recopilaron los cambios en las normativas del deporte, que pudieran tener impacto en las futuras lesiones. Resultados: Se observa que el número de lesiones se mantiene estable año tras año. Al asociar este dato con un aumento sostenido de la cantidad de jugadores por año, impresiona haber una disminución relativa del riesgo de lesionarse. Conclusiones: Las lesiones catastróficas generan un gran impacto en la calidad de vida del jugador y de su entorno. Deben considerarse inadmisibles y se deben incrementar los esfuerzos para lograr eliminar los riesgos de lesionarse. El esfuerzo de las entidades reguladoras impresiona tener un impacto positivo al haberse logrado una reducción relativa de las lesiones en relación con el aumento de jugadores año tras año. Nivel de Evidencia: IV


Introduction: A catastrophic injury is defined as any serious trauma that involves the head, brain, spine, or spinal cord. They are life-threatening or may leave a permanent or semi-permanent disability. In Argentina, there is a high incidence of injuries. materials and methods: Data obtained from a t elephone survey carried out in the collaborative framework between the Union Argentina de Rugby and the Fundación para la Lucha de Enfermedades Neurológicas de la Infancia (Fleni, by its acronym) were analyzed. We carried out a qualitative analysis of the data and their relationship to progressive changes in sports regulations. Results: It was observed that the number of injuries remained stable year after year. When associating this fact with a sustained increase in the number of players per year, we can see a relative decrease in the risk of injury. Conclusion: Catastrophic injuries have a gr eat impact on the quality of life of the player and his environment. They must be considered inadmissible and the efforts must be increased to achieve zero risk. In recent years, multiple preventive measures have been implemented and regulations have been modified in order to avoid catastrophic injuries. Level of Evidence: IV


Asunto(s)
Traumatismos en Atletas , Traumatismos de la Médula Espinal , Enfermedad Catastrófica , Fútbol Americano/lesiones , Fútbol Americano/estadística & datos numéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA